Trial Profile

Gut Microbiome and Oral Fluoropyrimidine Study in Patients With Colorectal Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Pembrolizumab (Primary) ; Tipiracil/trifluridine (Primary) ; Bevacizumab
Indications Adenocarcinoma; Colorectal cancer
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

29 Sep 2022 Status changed from active, no longer recruiting to completed.
08 Aug 2022 Planned End Date changed from 30 Jun 2023 to 28 Feb 2023.
08 Aug 2022 Planned primary completion date changed from 30 Jun 2023 to 28 Feb 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com